Guardant Health Inc.
Guardant Health Announces Strong Revenue Growth for 2025
Summary
On January 11, 2026, Guardant Health, Inc. announced preliminary unaudited financial results for the quarter and full year ended December 31, 2025. The company reported a 39% increase in total revenue for the fourth quarter, reaching approximately $280 million, and a 33% increase for the full year, reaching approximately $981 million. Additionally, oncology test volumes increased by 38% for the quarter and 34% for the full year, while Shield screening tests saw a significant increase from 6,400 tests in the prior year period to approximately 38,000 tests for the quarter and 87,000 tests for the full year. Guardant Health plans to report its fourth quarter and full year audited financial results during its February 2026 earnings call.
Profitelligence Alerts
Get alerts for GH
Be first to know when Guardant Health Inc. files with the SEC.
Filing Categories
Advertisement
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Official SEC Documents
Advertisement